Supernus Pharmaceuticals (SUPN) Cash from Operations Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) Cash from Operations Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -108.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -108.22% |
| Mar 31, 2026 | 117.41% |
| Dec 31, 2025 | -55.27% |
| Sep 30, 2025 | -215.22% |
| Jun 30, 2025 | 64.31% |
| Mar 31, 2025 | -20.32% |
| Dec 31, 2024 | -1.23% |
| Sep 30, 2024 | 49.18% |
| Jun 30, 2024 | 288.75% |
| Mar 31, 2024 | -21.83% |
| Dec 31, 2023 | 63.10% |
| Sep 30, 2023 | 159.19% |
| Jun 30, 2023 | -126.54% |
| Mar 31, 2023 | 1,041.93% |
| Dec 31, 2022 | -43.47% |
| Sep 30, 2022 | 436.76% |
| Jun 30, 2022 | 53.69% |
| Mar 31, 2022 | -88.12% |
| Dec 31, 2021 | 52.70% |
| Sep 30, 2021 | -173.41% |